Skip to main content
TVGN
NASDAQ Life Sciences

CEO Ryan Saadi Granted 50 Million Restricted Shares Tied to $1 Billion Revenue Target

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$5.72
Mkt Cap
$37.246M
52W Low
$3.636
52W High
$32.5
52W Position info
57% above low
Off High info
82% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

TVGN sits 57% above its 52-week low of $3.636 on light trading volume (0.3× avg).

Summary

Tevogen's CEO received 50 million restricted shares that vest only on $1.0 billion of cumulative revenue by 2031, and his reported beneficial ownership now stands at 91.1% of shares outstanding.


Key Events · Ownership and Investor Activity · TVGN

  • CEO Granted 50 Million Restricted Shares

    Under the 2024 Omnibus Incentive Plan, Tevogen granted Ryan Saadi 50,000,000 restricted shares on November 2, 2026 — roughly six times the 8,000,000 restricted shares granted in September 2026.

  • Vesting Requires $1 Billion Revenue

    The shares vest only on board certification of $1.0 billion in aggregate revenue from November 2, 2026 through December 31, 2031, and are automatically forfeited if the threshold is missed or service ends.

  • CEO Reports 91.1% Beneficial Ownership

    Saadi reports 61,709,567 shares, or 91.1% of the 67,765,267 shares outstanding as of November 4, 2026; 59,763,101 of those are restricted and cannot be sold.

  • Thin Public Float, Concentrated Control

    With the CEO reporting 91.1% of shares outstanding, the tradable float is small and public holders have minimal influence over votes and corporate actions.


Analysis · TVGN · Life Sciences

The headline number is the concentration: Saadi now reports beneficial ownership of 61,709,567 shares, or 91.1% of the 67,765,267 shares outstanding as of November 4, 2026, leaving public holders with a thin float and little say over corporate actions. That said, the award is not free money. Of those shares, 59,763,101 are restricted and cannot be sold, and the new 50,000,000-share tranche vests only if Tevogen books $1.0 billion in aggregate revenue between November 2, 2026 and December 31, 2031; miss the threshold or lose Saadi, and the shares are forfeited outright. Set that against a company that posted an $11.2M net loss and held $1.1M of cash in its August 10-Q, and the target looks like a very long reach. The practical read: the CEO's economics are now almost entirely tied to a binary outcome rather than to near-term share price.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TVGN was trading at $5.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.2M. The 52-week trading range was $3.64 to $32.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TVGN - Latest Insights

TVGN
Nov 16, 2026, 9:37 PM EST
Filing Type: S-3
Importance Score:
7
Price at Filing: $5.81
Real-time Price: $6.30 info
Change: +$0.490 (+8%) info
Market Cap: $432.676M info
TVGN
Nov 16, 2026, 5:24 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.22
Real-time Price: $6.30 info
Change: +$0.080 (+1%) info
Market Cap: $432.676M info
TVGN
Oct 08, 2026, 2:35 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $6.05
Real-time Price: $6.30 info
Change: +$0.2498 (+4%) info
Market Cap: $432.676M info
TVGN
Sep 16, 2026, 5:12 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.80
Real-time Price: $6.30 info
Change: -$1.50 (-19%) info
Market Cap: $432.676M info
TVGN
Aug 26, 2026, 3:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.69
Real-time Price: $6.30 info
Change: -$0.390 (-6%) info
Market Cap: $432.676M info